{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:41:35Z","timestamp":1793457695950,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICPis) have revolutionized cancer immunotherapy but also can induce autoimmune hemolytic anemia (AIHA), a severe disease with high mortality. However, the cellular and molecular mechanism(s) of AIHA secondary to ICPi therapy (ICPi-AIHA) are unclear, other than being initiated through decreased checkpoint inhibition. Herein, we report ICPi-AIHA in a novel mouse model that shows similar characteristics of known human ICPi-AIHA (eg, autoantibodies, hemolysis, and increased mortality). During ICPi-AIHA, there is the simultaneous reduction of 2 regulatory T-cell populations (FoxP3+ and Tr1 [type 1 regulatory cells]) and an increase in inflammatory T helper cell 17 (TH17). Moreover, a novel CD39+CD73\u2013FoxP3\u2013CD25\u2013 CD4+ T-cell subset (ie, CD39 single positive [CD39SP]) emerges, and early increases in CD39SP predict AIHA development; CD39 is an ectonuclease that breaks down adenosine triphosphate (ATP). Additionally, we found that boosting ATPase activity by injecting recombinant apyrase mitigates AIHA development and significant CD39SP reductions, both suggesting a functional role for CD39 and demonstrating a novel therapeutic approach. Importantly, CD39SP are detectable in multiple mouse models developing AIHA and in patients with AIHA, demonstrating applicability to idiopathic and secondary AIHA. Highlighting broader autoimmunity relevance, ICPi-treated NZB mice experienced accelerated onset and severity of lupus, including AIHA. Moreover, ICPi treatment of healthy B6 animals led to detectable CD39SP and development of autoantibodies against multiple autoantigens including those on red blood cells and platelets. Together, our findings provide further insight into the cellular and molecular mechanisms of ICPi-AIHA, leading to novel diagnostic and therapeutic approaches with translational potential for use in humans being treated with ICPi.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024230","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:28:04Z","timestamp":1722889684000},"page":"1581-1594","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Mitigation of checkpoint inhibitor\u2013induced autoimmune hemolytic anemia through modulation of purinergic signaling"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1921-0334","authenticated-orcid":false,"given":"Flavia","family":"Dei Zotti","sequence":"first","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Qiu","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivette D.","family":"D\u2019Agati","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwatina","family":"Jagnarine","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmalene","family":"Kyritsis","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-1655","authenticated-orcid":false,"given":"Anabel","family":"Miller","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tredicine","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daysha","family":"Fliginger","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-7957","authenticated-orcid":false,"given":"Elizabeth F.","family":"Stone","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Panch","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5663-9290","authenticated-orcid":false,"given":"Krystalyn E.","family":"Hudson","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2024101015205225500_bib1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024101015205225500_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2024101015205225500_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2024101015205225500_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2024101015205225500_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40425-017-0214-9","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"5","author":"Khan","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"2024101015205225500_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2024101015205225500_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"issue":"12","key":"2024101015205225500_bib8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3324\/haematol.2012.065144","article-title":"Partial tolerance of autoreactive B and T cells to erythrocyte-specific self-antigens in mice","volume":"97","author":"Hudson","year":"2012","journal-title":"Haematologica"},{"key":"2024101015205225500_bib9","doi-asserted-by":"crossref","first-page":"102489","DOI":"10.1016\/j.jaut.2020.102489","article-title":"Tolerization of recent thymic emigrants is required to prevent RBC-specific autoimmunity","volume":"114","author":"Wong","year":"2020","journal-title":"J\u00a0Autoimmun"},{"key":"2024101015205225500_bib10","doi-asserted-by":"crossref","first-page":"752330","DOI":"10.3389\/fimmu.2021.752330","article-title":"A\u00a0new murine model of primary autoimmune hemolytic anemia (AIHA)","volume":"12","author":"Dei","year":"2021","journal-title":"Front Immunol"},{"issue":"2-3","key":"2024101015205225500_bib11","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J\u00a0Autoimmun"},{"issue":"11","key":"2024101015205225500_bib12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood-2009-04-214387","article-title":"Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model","volume":"114","author":"Desmarets","year":"2009","journal-title":"Blood"},{"key":"2024101015205225500_bib13","doi-asserted-by":"crossref","first-page":"972127","DOI":"10.3389\/fimmu.2022.972127","article-title":"Distinct CD4+ T cell signature in ANA-positive young adult patients","volume":"13","author":"Dei Zotti","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2024101015205225500_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40478-018-0635-9","article-title":"Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1","volume":"6","author":"Coover","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"2024101015205225500_bib15","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3324\/haematol.2023.282815","article-title":"Reticulocytes in donor blood units enhance red blood cell alloimmunization","volume":"108","author":"Thomas","year":"2023","journal-title":"Haematologica"},{"key":"2024101015205225500_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-immunol-032712-100010","article-title":"The biology of recent thymic emigrants","volume":"31","author":"Fink","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2024101015205225500_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61737-979-6_2","article-title":"In\u00a0vitro Treg suppression assays","volume":"707","author":"Collison","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2024101015205225500_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","article-title":"Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection","volume":"40","author":"Crawford","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"2024101015205225500_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/eji.201847722","article-title":"Eomesodermin controls a unique differentiation program in human IL-10 and IFN-\u03b3 coproducing regulatory T cells","volume":"49","author":"Gruarin","year":"2019","journal-title":"Eur J Immunol"},{"issue":"7","key":"2024101015205225500_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2024101015205225500_bib21","doi-asserted-by":"crossref","first-page":"699069","DOI":"10.3389\/fimmu.2021.699069","article-title":"Editorial: purinergic signaling and inflammation","volume":"12","author":"Yuan","year":"2021","journal-title":"Front Immunol"},{"key":"2024101015205225500_bib22","doi-asserted-by":"crossref","first-page":"1032575","DOI":"10.3389\/fimmu.2022.1032575","article-title":"Type 1 regulatory T cell-mediated tolerance in health and disease","volume":"13","author":"Freeborn","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"2024101015205225500_bib23","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"issue":"10","key":"2024101015205225500_bib24","doi-asserted-by":"crossref","first-page":"eaah7152","DOI":"10.1126\/sciimmunol.aah7152","article-title":"Eomesodermin promotes the development of type 1 regulatory T (T(R)1) cells","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci Immunol"},{"issue":"22","key":"2024101015205225500_bib25","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.febslet.2015.07.027","article-title":"CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression","volume":"589","author":"Bono","year":"2015","journal-title":"FEBS Lett"},{"issue":"2","key":"2024101015205225500_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.hoc.2021.11.002","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"36","author":"Hwang","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"20","key":"2024101015205225500_bib27","first-page":"6029","article-title":"Diagnosis and management of autoimmune hemolytic anemias","volume":"11","author":"Barcellini","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"2024101015205225500_bib28","doi-asserted-by":"crossref","first-page":"1228142","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"2024101015205225500_bib29","first-page":"1244","article-title":"Epidemiology of secondary warm autoimmune haemolytic anaemia-a systematic review and meta-analysis","volume":"10","author":"Tranekaer","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"2024101015205225500_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2023.282859","article-title":"Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor alpha in autoimmune hemolytic anemia and participate in Th17 polarization","volume":"109","author":"Ciudad","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2024101015205225500_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun Ageing"},{"issue":"1","key":"2024101015205225500_bib32","doi-asserted-by":"crossref","first-page":"e000199","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don't","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"2","key":"2024101015205225500_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.autrev.2014.10.012","article-title":"Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions","volume":"14","author":"Grant","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2024101015205225500_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2024101015205225500_bib35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.exphem.2012.08.008","article-title":"Critical role of Th17 cells in development of autoimmune hemolytic anemia","volume":"40","author":"Xu","year":"2012","journal-title":"Exp Hematol"},{"issue":"10","key":"2024101015205225500_bib36","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"2024101015205225500_bib37","doi-asserted-by":"crossref","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"5","key":"2024101015205225500_bib38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","article-title":"Control of T(H)17\/T(reg) balance by hypoxia-inducible factor 1","volume":"146","author":"Dang","year":"2011","journal-title":"Cell"},{"issue":"9","key":"2024101015205225500_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/ph13090260","article-title":"Adenosine signaling in autoimmune disorders","volume":"13","author":"Magni","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024101015205225500_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fimmu.2016.00348","article-title":"Regulatory T cells are dispensable for tolerance to RBC antigens","volume":"7","author":"Richards","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"2024101015205225500_bib41","doi-asserted-by":"crossref","first-page":"102526","DOI":"10.1016\/j.autrev.2020.102526","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review","volume":"19","author":"Park","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2024101015205225500_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmg.39.8.537","article-title":"Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome","volume":"39","author":"Wildin","year":"2002","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"2024101015205225500_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152909789007043","article-title":"Helper T cells point the way to specific immunotherapy for autoimmune disease","volume":"9","author":"Hall","year":"2009","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"4","key":"2024101015205225500_bib44","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/eji.201040909","article-title":"Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome","volume":"41","author":"Passerini","year":"2011","journal-title":"Eur J Immunol"},{"issue":"4","key":"2024101015205225500_bib45","first-page":"297","article-title":"Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia","volume":"21","author":"Ahmad","year":"2011","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"7","key":"2024101015205225500_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.it.2016.04.009","article-title":"Regulation of the T cell response by CD39","volume":"37","author":"Takenaka","year":"2016","journal-title":"Trends Immunol"},{"issue":"9","key":"2024101015205225500_bib47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-beta signaling in Treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"2024101015205225500_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in\u00a0vivo","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat Immunol"},{"issue":"3","key":"2024101015205225500_bib49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/15\/1581\/2246224\/blood_bld-2024-024230-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/15\/1581\/2246224\/blood_bld-2024-024230-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T15:21:11Z","timestamp":1728573671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/15\/1581\/517043\/Mitigation-of-checkpoint-inhibitor-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024230","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}